Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed

Inclusion Criteria: * The informed consent form must be signed before any study specific tests or procedures are done * Confirmation of the subject's health insurance coverage prior to the first screening visit * Healthy male subject * Ethnicity: Caucasian * Age: 18 to 45 years (inclusive) at the first screening visit * Body mass index (BMI) above or equal 18, and below or equal 29.9 kg / m² * Ability to understand and follow study-related instructions Exclusion Criteria: * Suspicion of drug or alcohol abuse * Regular daily consumption of more than 1 L of xanthin-containing beverages * Intake of foods or beverages containing grapefruit within 2 weeks prior to the first study drug administration (the same applies to pomelos and St. John's Wort) * Use of medication within 4 weeks prior to the first study drug administration which could interfere with the investigational products (e.g. CYP3A inhibitors or CYP3A inducers) * examples for CYP3A inhibitors: erythromycin, inhibitors of human HIV protease (e.g. ritonavir, saquinavir), amiodarone, diltiazem, verapamil, fluconazole, itraconazole, ketoconazole, clarithromycin, telithromycin, nefazodon, cimetidine; * examples for CYP3A inducers: rifampicin, carbamazepin, phenytoin, phenobarbital, or products containing St. John's Wort; * Systolic blood pressure below 116 or above 145 mmHg (after at least 15 min supine) * At the first screening visit * Diastolic blood pressure above 95 mmHg (after at least 15 min supine) * Heart rate below 45 or above 95 beats / min (after at least 15 min supine) at the first screening visit * Clinically relevant findings in the physical examination * Positive urine drug screening or alcohol breath test * Exclusion periods from other studies or simultaneous participation in other clinical studies